{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:11:12Z","timestamp":1784016672032,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10072-021-05850-7","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:03:06Z","timestamp":1643500986000},"page":"2845-2848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Neurofilament light chain as a\u00a0disease severity biomarker in ATTRv: data from a single-centre experience"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Paolantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Guglielmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serenella","family":"Servidei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Primiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"5850_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A et al (2020) Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag 16:109\u2013123","journal-title":"Ther Clin Risk Manag"},{"key":"5850_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","volume":"27","author":"M Russo","year":"2020","unstructured":"Russo M, Obici L, Bartolomei I et al (2020) ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid 27:259\u2013265","journal-title":"Amyloid"},{"key":"5850_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589","journal-title":"Nat Rev Neurol"},{"key":"5850_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/acn3.51355","volume":"8","author":"A Gauthier","year":"2021","unstructured":"Gauthier A, Viel S, Perret M et al (2021) Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis. Ann Clin Transl Neurol 8:1141\u20131150","journal-title":"Ann Clin Transl Neurol"},{"key":"5850_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90:870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5850_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/13506129.2018.1545640","volume":"25","author":"M Luigetti","year":"2018","unstructured":"Luigetti M, Bisogni G, Romano A et al (2018) Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre. Amyloid 25:242\u2013246","journal-title":"Amyloid"},{"key":"5850_CR7","doi-asserted-by":"crossref","unstructured":"Salvalaggio A, Coraci D, Obici L, et al. (2021) Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. J Neurol","DOI":"10.1007\/s00415-021-10754-9"},{"key":"5850_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor M, Foiani M, Heslegrave A et al (2019) Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst 24:314\u2013319","journal-title":"J Peripher Nerv Syst"},{"key":"5850_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia LF, Maceski A, Concei\u00e7\u00e3o I et al (2020) Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27:97\u2013102","journal-title":"Amyloid"},{"key":"5850_CR10","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau S, Sridharan GV, Tsour S et al (2021) Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96:e412\u2013e422","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T07:15:41Z","timestamp":1647069341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5850"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05850-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Universit\u00e0 Cattolica del Sacro Cuore di Roma\u2019s Ethics Committee. All patients in the study submitted an informed consent. This study was carried out according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Dr Luigetti received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and Pfizer, and travel grants from Akcea, Alnylam, Sobi, Pfizer, Kedrion, Csl Behring, and Grifols; Dr Di Paolantonio received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and travel grants from Akcea; Dr Guglielmino reported no disclosures; Dr Romano received financial grants (honoraria and speaking) from Ackea, and travel grants from Akcea and Alnylam; Dr Rossi received a grant partially funded by the Associazione Italiana Vivere la Paraparesi Spastica (AIViPS) Onlus; Dr Andrea Sabino reported no disclosures; Dr Servidei reports no disclosures; Dr Sabatelli received financial grants (honoraria and speaking) from Ackea; Dr Primiano reported no disclosures. This study was not funded.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}